calendar
83 catalysts · 3,827 phase readout · 2,121 8k filing · 277 earnings · 172 phase 2 completion · 133 drug shortage · 109 grant
83 catalysts · 3,827 phase readout · 2,121 8k filing · 277 earnings · 172 phase 2 completion · 133 drug shortage · 109 grant
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: DR REDDYS LABS SA. Form: FILM. Route: BUCCAL, SUBLINGUAL
Sponsor: GE HLTHCARE INC. Form: SOLUTION. Route: INTRAVENOUS
Sponsor: GENENTECH INC. Form: TABLET. Route: ORAL
Sponsor: MANKIND PHARMA. Form: SOLUTION/DROPS. Route: OPHTHALMIC
Sponsor: RK PHARMA. Form: TABLET. Route: ORAL
Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION
Sponsor: EXTROVIS. Form: SOLUTION. Route: INTRAVENOUS
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: NOVARTIS PHARMS CORP. Form: INJECTABLE. Route: INJECTION
Sponsor: QUAGEN. Form: SYRUP. Route: ORAL
Sponsor: YICHANG HUMANWELL. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: GLENMARK SPECLT. Form: CREAM. Route: TOPICAL
Sponsor: MARKSANS PHARMA. Form: CAPSULE, DELAYED RELEASE. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: GLENMARK PHARMS LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Sponsor: IMPAX LABS. Form: CAPSULE. Route: ORAL
Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL
Therapy area: Oncology. Indication: Hormone-Sensitive Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Prostate Cancer, Prostate Cancer
Sponsor: ABBVIE. Form: IMPLANT. Route: INTRAVITREAL
Sponsor: ACCORD HLTHCARE. Form: TABLET, EXTENDED RELEASE. Route: ORAL
Sponsor: AUROBINDO PHARMA. Form: CAPSULE. Route: ORAL
Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Myelodysplastic Syndrome (Preleukemia)
Therapy area: Oncology. Indication: Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-Cell Lymphoma
Therapy area: Gastrointestinal. Indication: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)
Therapy area: Cardiovascular, Gastrointestinal. Indication: Endothelial Dysfunction, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD)
Sponsor: NOVARTIS. Form: TABLET. Route: ORAL